A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.

Epizyme and its partners have moved two programs into the clinic and will start an expansion trial for the DOT1L program later this year. It has also struck deals for companion diagnostics, making steady progress personalized medicine solutions for patients with genetically defined cancers within five years of starting clinical trials. CEO Robert Gould and Exec VP Jason Rhodes take stock of the company’s progress.

Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.